RT Journal Article
SR Electronic
T1 Significance of Glasgow Prognostic Scores in NSCLC Patients Treated With Immunotherapy After Platinum-based Cytotoxic Chemotherapy
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 3423
OP 3430
DO 10.21873/invivo.12642
VO 35
IS 6
A1 HYE SEON KANG
A1 AH YOUNG SHIN
A1 CHANG DONG YEO
A1 SUNG KYOUNG KIM
A1 CHAN KWON PARK
A1 JU SANG KIM
A1 SEUNG JOON KIM
A1 SANG HAAK LEE
A1 JIN WOO KIM
YR 2021
UL http://iv.iiarjournals.org/content/35/6/3423.abstract
AB Background/Aim: Little is known about the prognostic role of the Glasgow prognostic score (GPS) in non-small cell lung cancer (NSCLC) patients treated with immunotherapy after platinum-based cytotoxic chemotherapy. Patients and Methods: This study used a lung cancer cohort of the Catholic Medical Center of Korea between January 2018 and September 2020. Results: A total of 78 patients with NSCLC treated with immunotherapy as second or further-line therapy were included. Higher GPS values were significant predictors of shorter immune-related progression-free survival (irPFS) and overall survival (OS). The hazard ratios for irPFS were 0.249 for programmed death-ligand 1 (PD-L1) expression ≥50% and 9.73 for a GPS of 2. Older age, lower PD-L1 expression and higher GPS values were independently associated with shorter OS. Conclusion: Higher GPS values were identified as a poor prognostic factor for OS and irPFS in NSCLC patients who received immunotherapy as second or further-line therapy.